2016_BT PROSTATE CANCER COURSE BOOK

• Intermediate-risk patients should be considered on an individual case basis . I di i k i i h • nterme ate-r s pat ents w t favorable features may appropriately be treated with PPB monotherapy but results from confirmatory clinical trials are pending.